136 related articles for article (PubMed ID: 27255997)
1. MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.
Xie S; Zheng H; Wen X; Sun J; Wang Y; Gao X; Guo L; Lu R
Biochem Biophys Res Commun; 2016 Aug; 476(4):493-500. PubMed ID: 27255997
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MUS81 improves the chemical sensitivity of olaparib by regulating MCM2 in epithelial ovarian cancer.
Zhong A; Zhang H; Xie S; Deng M; Zheng H; Wang Y; Chen M; Lu R; Guo L
Oncol Rep; 2018 Apr; 39(4):1747-1756. PubMed ID: 29393493
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
4. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
[TBL] [Abstract][Full Text] [Related]
5. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):132-5. PubMed ID: 18683754
[TBL] [Abstract][Full Text] [Related]
6. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
8. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
9. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
12. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
15. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
[TBL] [Abstract][Full Text] [Related]
16. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
Reed E; Yu JJ; Davies A; Gannon J; Armentrout SL
Clin Cancer Res; 2003 Nov; 9(14):5299-305. PubMed ID: 14614013
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
18. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
19. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
20. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]